Clinical trial
Natalizumab in Combination With Glatiramer Acetate (GA) in Patients With…
NCT00097760 · Biogen, Industry · Completed
Key facts
| NCT number | NCT00097760 |
|---|---|
| Title | Natalizumab in Combination With Glatiramer Acetate (GA) in Patients With Relapsing-Remitting Multiple Sclerosis |
| Official title | Safety Study of Natalizumab in Combination With Glatiramer Acetate (GA) |
| Lead sponsor | Biogen, Industry |
| Collaborators | Elan Pharmaceuticals Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Multiple Sclerosis, Relapsing-Remitting |
| Intervention type | Drug |
| Interventions | Natalizumab, Placebo |
| Enrollment | 110 |
| Start date | Jun 1, 2003 |
| Primary completion | Mar 1, 2004 |
| Completion | Mar 1, 2004 |
| First posted | Dec 1, 2004 |
| Last update posted | Jun 18, 2009 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: